Low-risk neuroblastoma (INRG very low and low risk, including stage MS)

What changed: Low-risk neuroblastoma (INRG very low and low risk, including stage MS)

Every dated change on the records linked to Low-risk neuroblastoma (INRG very low and low risk, including stage MS), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Milestone4This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordLow-risk neuroblastoma (INRG very low and low risk, including stage MS)
Facts on this page last checked
When this page itself was last checked or edited.

2012 · 1

2012MilestoneActive surveillance
P9641: surgery alone gives 97 percent survival in low-risk disease; expectant observation of small adrenal masses reported
A milestone in how this cancer is treated.

2009 · 1

2009MilestoneINRG staging and risk groups
International Neuroblastoma Risk Group classification published
A milestone in how this cancer is treated.

2008 · 1

2008MilestoneLow-risk neuroblastoma (INRG very low and low risk, including stage MS)
German NB97: spontaneous regression in about half of observed infant tumours
A milestone in how this cancer is treated.

1971 · 1

1971MilestoneLow-risk neuroblastoma (INRG very low and low risk, including stage MS)
Evans staging of neuroblastoma introduced; stage IV-S recognised as regressing disease
A milestone in how this cancer is treated.